COMP <GO>
UPC vs IMRN // EV/EBITDA & P/E VALUATION
Universe Pharmaceuticals Inc. (Class A) (NASDAQ) VS. Immuron Limited (NASDAQ) • 15-METRIC TALLY: UPC 1
— IMRN 1
■ METRIC PARITY
LAST: $1.54 (-20.21%) • MKT CAP: $7.7M
valuation
—
LAST: $0.92 (+2.48%) • MKT CAP: $7.4M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (UPC VS. IMRN)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | UPC | IMRN | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 35.30% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | — | — | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -16.30% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -20.60% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | -22.40% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | — | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 22.2 | 32.0 | -9.79 | IMRN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $7.7M | $7.4M | $292.7K | UPC | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | UPC REV | IMRN REV | UPC GROSS % | IMRN GROSS % | UPC FCF | IMRN FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $17.86B | — | 35.3% | — | -$5.32B | — |
| FY 2024 | $23.02B | — | 26.4% | — | -$9.72B | — |
| FY 2023 | $32.31B | — | — | — | $1.12B | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
UPC // BETA —
IMRN // BETA —